SECTION 03 / DOSE LITERATURE
How BPC-157 dosage is expressed in the research literature
Per-body-weight animal figures, the routes studied, the pharmacokinetics, and the gastric-stability rationale for oral interest — research context, never a human protocol.
How BPC-157 doses are expressed in the research literature
BPC-157 dosage in the published record is expressed per body weight in animals, not as a human dose. Rodent studies commonly use figures around 10 microg/kg and 10 ng/kg, and tendon work has gone as low as 10 pg per rat [1]. The foundational gastric-ulcer cytoprotection study used 400 ng/kg and 800 ng/kg in rats [4]. These are animal-model figures reported in studies; they are not dosing guidance, and this bulletin does not convert them into a human regimen.
Human pilot data are minimal and do not establish a dose: a 2-participant intravenous safety pilot used 10 mg then 20 mg by infusion [7], and an interstitial-cystitis pilot used a single 10 mg intravesical dose during cystoscopy [9]. There is no validated human dose, duration, or schedule for BPC-157.
BPC-157 half-life and pharmacokinetics
BPC-157 half-life and pharmacokinetics
The BPC-157 half life question has one clean answer in the animal record. The first formal pharmacokinetic, distribution, metabolism, and excretion study, in rats and beagle dogs, reported an elimination half-life under 30 minutes, linear pharmacokinetics across doses, intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, and excretion via urine and bile, with the peptide breaking down into small fragments that enter normal amino-acid metabolism [2]. The short half-life is a settled point in the animal data and one of the most-cited facts about the molecule.
That clearance speed is why the question of duration is awkward: the peptide leaves the system in well under an hour, yet healing endpoints in animals are measured over days to weeks of repeated dosing [1]. The literature attributes the gap to downstream signaling rather than peptide persistence [3].
Oral and peroral BPC-157 in the research literature
Oral and peroral BPC-157 in the research literature
BPC-157 oral and peroral administration is studied because the peptide is termed a "stable gastric pentadecapeptide" — it is reported stable in human gastric juice, which is the rationale for the route [2]. In the foundational gastric-ulcer model, though, intramuscular delivery outperformed intragastric for ulcer healing [4], and formal human oral pharmacokinetics are not established [2].
Can BPC-157 be taken orally?
It is studied in animal gastrointestinal and systemic models on the strength of its gastric-juice stability, and intragastric dosing appears in the rodent record [4]; in that foundational ulcer model intramuscular outperformed intragastric, and formal human oral pharmacokinetics are not established [2]. ### Does oral BPC-157 work? Oral and peroral dosing is studied in animals on the basis of gastric stability, but its real-world oral efficacy in humans is not established by controlled data [6].
Bioavailability, and why the route matters in the data
Route is not a side note in the BPC-157 literature; it changes the numbers. The pharmacokinetic study reported intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs — a wide species gap that, on its own, complicates any attempt to read across to humans [2]. In the foundational gastric-ulcer model, intramuscular delivery outperformed intragastric for ulcer healing, even though the peptide's gastric stability is what makes oral routes interesting in the first place [4].
That tension — a stable gastric pentadecapeptide whose best-documented healing came from injection rather than ingestion — is one the literature has not resolved with human data, because formal human oral pharmacokinetics are not established [2]. The honest reading is that route-dependent behavior is real in the animal record and unmeasured in people.
Routes studied and handling, in research context
The routes that appear in the BPC-157 record are intraperitoneal (most common in rodent work), intramuscular, intragastric and peroral, local and intra-lesional, intravenous (the human safety pilot), intravesical (the interstitial-cystitis pilot), and intra-articular (the knee-pain case series) [1][7][9][10]. The spread of routes reflects how many injury models the peptide has been tested in, not a recommended administration method.
The peptide is commonly supplied as the acetate salt and handled as a lyophilized powder reconstituted in a diluent for research [4]. Storage and reconstitution practices described in research papers are laboratory handling, not validated clinical protocols, and nothing on this page is a use instruction. The bulletin documents how doses and routes are reported in studies; it does not advise administering the peptide to anyone.